ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Antibody-drug Conjugate IPN60300

Its studies are mostly in Neoplasm Metastasis, led by Ipsen.

Furthest: phase 2, since Oct 1, 20251 company-led study, 1 open or runningNext primary completion: Oct 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ipsen11 open or runningphase 2since Oct 1, 2025Oct 1, 2025Oct 30, 2028phase 2 · NCT07213817

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 1, 2025First study: phase 2 study in Neoplasm MetastasisFirst studyNCT07213817 · 114 planned · United States, France, Spain

Ahead

  1. Oct 30, 2028Primary completion: phase 2 study in Neoplasm MetastasisNCT07213817

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07213817Neoplasm Metastasis · United States, France, Spain2RecruitingOct 30, 2028114

How it is read

Names in the registry

  • “IPN60300”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.